Recombinant factor VIIa for intractable life-threatening bleeding in patients with circulatory assist devices


Dear Editor, Circulatory assist devices require tight anticoagulation therapy and may be complicated by severe bleeding. Despite warnings related to potential lethal thrombotic complications, offlabel use of recombinant factor VIIa (rFVIIa) is increasingly reported for refractory hemorrhage, including after cardiac surgery [1, 2]. However, its use in patients with circulatory assist devices has seldom been reported and its safety remains to be established [3–5]. We reviewed 12 consecutive patients with surgically implanted devices who received rFVIIa as rescue treatment for intractable lifethreatening bleeding between March 2004 and November 2009 (Table 1). According to strict and constringent local consensus guidelines, a systematic cross-check for aggressive correction of hypothermia, acidosis, and coagulation factors with parallel surgical control for bleeding or embolization was obtained before rFVIIa administration in all cases. The median age of patients was 45 years. The rFVIIa was administered in the operating room (3/12), in the intensive care unit (7/12), or both (2/12). Underlying conditions were cardiovascular surgery (11/12, including 4 heart transplantations) and bipulmonary transplantation (1/12). The device was an extracorporal membrane oxygenator (9/12) and a left ventricular assist device (3/12). Median dose of rFVIIa was 95 lg/kg (45–180), administered in one (3/12) or several doses (9/12). In these otherwise terminal patients, the bleeding assessed by the number of ml/kg of packed red blood cells and fresh frozen plasma requirement within 12 h before and after rFVIIa administration was significantly reduced. Six patients (50%) died within 30 days, including 2 (18%) from persistent bleeding. A careful analysis of coagulation and other physiological parameters did not reveal significant difference between responders and non-responders.

DOI: 10.1007/s00134-010-1937-y

1 Figure or Table

Cite this paper

@article{Schneider2010RecombinantFV, title={Recombinant factor VIIa for intractable life-threatening bleeding in patients with circulatory assist devices}, author={Antoine Schneider and Marie-H{\'e}l{\`e}ne P{\'e}rez and Piergiorgio Tozzi and Pierre Voirol and Patrick Schoettker and Anne Angelillo-Scherrer and Jacques Cotting and Ludwig Karl von Segesser and Philippe Eggimann}, journal={Intensive Care Medicine}, year={2010}, volume={36}, pages={1620-1621} }